Physician profile
Nerissa Licup
NPI 1720269731
$4,464.12
in general payments reported to CMS, 2019-2025
36 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $829 · 2021: $1,364 · 2022: $479 · 2023: $90.50 · 2024: $304 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $627.06 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $521.03 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $315.12 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $306.00 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $223.02 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.08 | 2019-2022 | |
| Lilly USA, LLC | $189.09 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Pfizer INC. | $179.39 | 2019-2022 | |
| Astellas Pharma US INC | $177.69 | 2019-2021 | |
| Amarin Pharma, INC. | $155.42 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $144.66 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.29 | 2019-2024 | Xifaxan |
| Allergan, INC. | $133.28 | 2020 | |
| Inogen, INC. | $113.45 | 2023-2025 | Inogen At Home Stationary Concentrator |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $86.85 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $75.49 | 2019 | |
| Mylan Specialty L.P. | $67.59 | 2019-2020 | |
| Eisai INC. | $63.46 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $58.93 | 2019-2025 | Rexulti |
| Lundbeck LLC | $53.76 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $45.01 | 2019-2021 | |
| Exact Sciences Corporation | $42.91 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $35.79 | 2021 | |
| Medtronic Minimed, INC. | $31.51 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $30.45 | 2020-2022 | |
| Dexcom, INC. | $29.42 | 2022 | |
| Philips North America LLC | $28.90 | 2024 | (Ck7) Extended Holter |
| Xeris Pharmaceuticals, INC. | $24.01 | 2025 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $22.25 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.17 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.24 | 2021 | |
| Circassia INC. | $13.77 | 2019 | |
| Agile Therapeutics, INC. | $12.50 | 2021 | |
| Amgen INC. | $12.27 | 2020 | |
| Biodelivery Sciences International, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nerissa Licup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.